Click Therapeutic announced a $52 million Series B funding round, Mobi Health News reports. H.I.G. BioHealth Partners and Accelmed Partners ll led the round, with participation from Health Catalyst Capital, Revelation Partners, Sanofi, K2 HealthVentures, Hima Ventures and RdigetopHealth.
This news comes over a year after the company inked a $500 million-plus deal with pharma company Boehringer Ingelheim to jointly commercialize a digital treatment for patients with schizophrenia.
Click Therapeutic is focused on providing software as a prescription therapy for a number of conditions. The company got its start in smoking cessation, and quickly expanded to include other mental health conditions including major depressive disorder, insomnia and schizophrenia. Read more.
